Patents by Inventor Tim Walseth

Tim Walseth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20220204636
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 14, 2021
    Publication date: June 30, 2022
    Inventors: Michel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
  • Antibodies against human CD38
    Patent number: 11230604
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 25, 2022
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20180298106
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 18, 2018
    Inventors: Michel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
  • Antibodies against human CD38
    Patent number: 9944711
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 17, 2018
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20160237161
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: January 8, 2016
    Publication date: August 18, 2016
    Inventors: Michel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
  • Antibodies against human CD38
    Patent number: 9249226
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: February 2, 2016
    Assignee: GENMAB A/S
    Inventors: Michel de Weers, Tim Walseth, Jan van de Winkel, Tom Vink, Paul Parren
  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20130209355
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 8, 2011
    Publication date: August 15, 2013
    Applicant: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • TRPM2-specfic inhibitors
    Publication number: 20080114079
    Abstract: The present invention relates to methods and compositions for modulating ADPR-mediated migratory activity of cells through regulation of the TRPM2 cation channel. Such methods and compositions may be used for the treatment of disorders including, but not limited to, inflammation, ischemia, atherosclerosis, asthma, autoimmune disease, diabetes, arthritis, allergies, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages, monocytes and dendritic cells. The invention further relates to specific inhibition of TRPM2 by blocking the activity of ADPR. The invention also relates to drug screening assays designed to identify compounds that regulate TRPM2 and thereby also function to modulate ADPR-mediated cell migration. The invention is based on the discovery that, 8Br-ADPR, which specifically inhibits activation of TRPM2, acts to inhibit ADPR-mediated cell migration.
    Type: Application
    Filed: January 10, 2007
    Publication date: May 15, 2008
    Inventors: Frances E. Lund, Santiago Partida-Sanchez, Tim Walseth